HomeTWST • NASDAQ
add
Twist Bioscience Corp
Previous close
$31.09
Day range
$30.58 - $31.79
Year range
$23.30 - $55.33
Market cap
1.83B USD
Avg Volume
1.87M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 99.01M | 16.88% |
Operating expense | 80.77M | 8.74% |
Net income | -27.14M | 21.69% |
Net profit margin | -27.41 | 33.00% |
Earnings per share | -0.45 | 23.73% |
EBITDA | -26.83M | 16.12% |
Effective tax rate | -0.96% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 232.43M | -15.91% |
Total assets | 641.86M | 4.48% |
Total liabilities | 168.90M | 19.25% |
Total equity | 472.96M | — |
Shares outstanding | 61.15M | — |
Price to book | 3.99 | — |
Return on assets | -11.64% | — |
Return on capital | -13.19% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -27.14M | 21.69% |
Cash from operations | -11.81M | 22.89% |
Cash from investing | -12.40M | -865.21% |
Cash from financing | 5.57M | 53.68% |
Net change in cash | -18.48M | -43.20% |
Free cash flow | -14.59M | -124.74% |
About
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Founded
2013
Website
Employees
979
